US Patent 10,383,846 Scope, Claim Boundaries, and Hyperhidrosis Topical Glycopyrrolate-Comparability Patent Landscape
Executive summary: US Patent 10,383,846 claims a topical, bedtime-before administration method for hyperhidrosis using a specific glycopyrrolate prodrug/ester set (two named pyrrolidinium bromide compounds) at ~1% to ~25% in a pharmaceutically acceptable vehicle, with sweat-reduction performance tied to (i) ≥25% reduction for ≥6 hours and (ii) performance equivalency versus topical glycopyrrolate at the same concentration, while also requiring an improved safety profile versus topical glycopyrrolate. The claim scope is method-of-treatment/dosing and is tightly constrained by (a) timing (before bedtime, optional second dose 6–10 hours later), (b) specific actives, and (c) quantified efficacy and relative-safety/comparability language. The estate’s value for challengers centers on whether competitors’ products can design around by avoiding one or more of the required elements (compound identity, vehicle/solvent features where recited, ethanol/isopropyl alcohol where recited, dosing schedule, sweat reduction thresholds, and the “improved safety” and “substantially equivalent reduction” comparative limitations).
What does US Patent 10,383,846 claim for topical hyperhidrosis treatment in the US?
Answer (scope in one paragraph): US 10,383,846 is directed to US method-of-use and dosing claims for hyperhidrosis that require topically administering a composition containing one of two specified compounds (named glycopyrrolate-related pyrrolidinium bromide derivatives) at about 1.0% to about 25% to a hyperhidrotic skin area before bedtime, achieving ≥25% sweat reduction for ≥6 hours and achieving sweat reduction that is substantially equivalent to an amount obtained with a topical glycopyrrolate composition at the same concentration, while also having an improved safety profile compared with topical glycopyrrolate. Dependent claims carve out human subjects, sweat-reduction ranges, formulation types, anatomic sites, ethanol/solvent specifics, and optional repeat dosing 6–10 hours later.
Core independent claim structure (Claims 1 and 8)
Both independent claims track the same technical requirements, with Claim 1 framed as a method of treating and Claim 8 framed as a method of dosing.
Independent claim elements (Claim 1 / Claim 8):
- Actives (exclusive set): a compound selected from:
- (i) 3-(2-cyclopentyl-2-phenyl-2-hydroxyacetoxy)-1-(methoxycarbonylmethyl)-1-methylpyrrolidinium bromide
- (ii) 3-(2-cyclopentyl-2-phenyl-2-hydroxyacetoxy)-1-(ethoxycarbonylmethyl)-1-methylpyrrolidinium bromide
- Concentration band: about 1.0% to about 25% of the selected compound.
- Formulation: composition comprising a pharmaceutically acceptable vehicle (vehicle itself is not limited in the independent claim).
- Route/target: topically administering to skin of an area suffering from hyperhidrosis.
- Timing: before bedtime.
- Efficacy requirement 1: sweat production reduced by at least about 25% for at least about six hours.
- Comparative efficacy requirement 2 (relative equivalency): sweat reduction is substantially equivalent to sweat reduction achieved with topical glycopyrrolate at the same concentration.
- Relative safety requirement: an improved safety profile compared to topical glycopyrrolate.
Implication for claim boundary: The independent claims are not just “topical glycopyrrolate-derivative at X%.” They are a performance-validated relative-comparison claim whose measurable endpoints include (i) time-bound sweat reduction and (ii) equivalency and (iii) comparative safety.
How narrow or broad are the claim limitations in US 10,383,846?
Answer: Moderately narrow on actives and dosing structure, broad on formulation form (vehicle unspecified), but still narrowed by multiple performance/timing/comparative limitations that are difficult to avoid in practice.
Where competitors can design around
The most “design-aroundable” limitations are:
- Active identity: only the two explicitly named pyrrolidinium bromides fall within the claim set. A competitor using a different glycopyrrolate prodrug, salt, or ester would not literally infringe Claims 1/8.
- Timing: “before bedtime” is an express dosing condition. Competitors dosing at different times could avoid literal infringement, though some doctrine-of-equivalents arguments may remain depending on claim construction.
- Quantified sweat-reduction performance: at least 25% reduction for ≥6 hours (and dependent claims add additional ranges/durations).
- Comparative equivalency to topical glycopyrrolate at the same concentration: this is an additional evidentiary requirement that can become a litigation battleground.
- “Improved safety profile” vs topical glycopyrrolate: another comparative limitation that typically demands specific clinical or nonclinical safety evidence at least at the claim-construction stage.
Where competitors have less flexibility
- Vehicle/formulation form in the independent claim is broad (dependent claims list examples including gels, creams, lotions, foam, solutions, emulsions, etc.).
- Concentration band is wide (1% to 25%), limiting simple “low-dose” design around unless below 1% or using a non-covered compound.
What compounds are covered by US 10,383,846 and how does the claim compare to topical glycopyrrolate?
Answer: The patent claims two specific glycopyrrolate-related pyrrolidinium bromides (methoxycarbonylmethyl and ethoxycarbonylmethyl variants). It requires that the resulting sweat reduction is substantially equivalent to topical glycopyrrolate at the same concentration, while also improving safety.
Claim-driven comparison construct
The independent claims build a three-part relationship:
- Positive clinical endpoint: sweat reduction ≥25% for ≥6 hours.
- Cross-product equivalency: sweat reduction “substantially equivalent” to glycopyrrolate at the same concentration.
- Safety advantage: improved safety profile versus topical glycopyrrolate.
Litigation impact: In validity/infringement disputes, both sides can fight over:
- What test methods define “sweat production,”
- What “substantially equivalent” means quantitatively,
- What “improved safety” includes (local irritation, systemic anticholinergic effects, tolerability metrics),
- Whether competitor products match the required endpoint profile.
Which dependent claim features further constrain US 10,383,846 (formulation, sites, dosing, solvents)?
Answer: Dependent claims add optional but meaningful limitations on: human subject, % reduction ranges, duration windows (8–24 hours; 8–12 hours), anatomic application areas, formulation types, specific 5% ethanol/70% ethanol embodiment, repeat dosing (6–10 hours), and solvent system (ethanol or isopropyl alcohol).
Key dependent claims (high signal for design-around and product mapping)
Claim 2 (adds):
- Human subject
- Sweat reduction ~25% to ~99%
- Formulation may be solid/semi-solid/powder/gel/cream/lotion/foam/solution/suspension/emulsion
- Sweat reduction from ~8 hours to ~24 hours
- Application to superficial areas: palm, plantar, groin, axilla, facial
Claim 3 (adds):
- Sweat reduction ~30% to ~75%
- Formulation containing ~2% to ~10% compound
- Sweat reduction from ~8 hours to ~12 hours
Claim 4 (adds):
- Sweat reduction ~45% to ~60%
- Formulated as 5% solution of compound in 70% ethanol
Claim 5:
- Sweat production reduced by about 50% (a narrower performance point)
Claim 6:
- Second topical dose within 6–10 hours after initial bedtime dosing
Claim 7 (adds to compound concentration and solvent):
- Formulated with ~2% to ~10% compound
- ~5% solution in 70% ethanol
Claim 15–18 (solvent system variants):
- Claim 15: composition uses isopropyl alcohol or ethanol alone as solvent or co-solvent with water
- Claim 16: solvent is ethanol alone
- Claim 17: same as 15 but tied to Claim 8 structure
- Claim 18: solvent is ethanol alone
Claims 19–22 (dosing frequency regimes):
- Claim 19: administered 1 to 4 times daily
- Claim 20: administered once or twice daily
- Claim 21–22: same framework for Claim 8
Design-around leverage from dependent claims
If a competitor can avoid matching enough dependent features, they can attempt to fall outside particular dependent claim coverage even if independent claim coverage is disputed.
The most product-specific “hooks”:
- 70% ethanol and 5% solution (Claims 4 and 7),
- ethanol-only solvent (Claims 16 and 18),
- repeat dosing window 6–10 hours (Claim 6 and 13).
What is the practical claim “read” for a competitor product label and dosing instructions?
Answer: A literal infringement posture becomes higher risk if a product:
- uses one of the two exact compounds,
- at 1–25%,
- delivered topically to the targeted hyperhidrosis area,
- directed to be applied before bedtime,
- shows sweat reduction at least 25% for ≥6 hours, and
- produces outcomes “substantially equivalent” to topical glycopyrrolate at the same concentration with an improved safety profile.
Label and regimen mapping:
- “Before bedtime” is explicit. A regimen that is purely daytime could be a design-around.
- “Once/twice daily” or “1–4 times daily” can still sit inside the dependent claim set, but independence already anchors “before bedtime.”
- A two-dose regimen can increase risk if the second application lands in the 6–10 hour post-initial window.
How strong is the US patent estate around 10,383,846 for topical hyperhidrosis?
Answer: The strength assessment cannot be completed from the provided claim text alone because patent estate strength depends on the patent family, related priority applications, prosecution history, and co-pending or related US continuations and divisionals. Without those bibliographic and family records, only the internal claim-structure strength can be evaluated: the claim is performance-anchored and has several relative-comparison limitations, which often increases evidentiary burden for infringement and can narrow the set of infringing embodiments.
Internal strength signals in the claims
- Multiple quantitative endpoints (≥25% for ≥6 hours; dependent time bands and % ranges).
- Relative-performance framing to topical glycopyrrolate at the same concentration.
- Relative-safety framing to topical glycopyrrolate.
- Explicit actives set and bromide salt forms.
Internal vulnerability signals in the claims
- Comparative limitations can create arguments about:
- test methodology,
- reference product selection,
- matching “same concentration,”
- safety metric definitions.
- Timing limitation (“before bedtime”) can be used as a noninfringement lever.
What US Orange Book status would apply to a method-of-use patent like 10,383,846?
Answer: The provided information does not include the drug name, NDA/BLA reference product, or Orange Book listing. The patent appears to be a method-of-treatment/dosing claim tied to topical compositions for hyperhidrosis, but Orange Book status requires a specific FDA product linkage (application number, listed patents, and claim-to-use mapping).
Because that linkage is not provided, a complete Orange Book status determination cannot be produced.
Which generics or Paragraph IV challenges would plausibly risk infringement of US 10,383,846?
Answer: Plausible risk profiles are those where an ANDA or 505(b)(2) product is a topical hyperhidrosis drug that:
- uses the same two pyrrolidinium bromide compounds (or equivalents that could be argued as the same compound),
- uses 1–25% concentration,
- is dosed before bedtime,
- and achieves at least 25% sweat reduction for ≥6 hours with substantially equivalent outcomes to topical glycopyrrolate and improved safety.
High-risk competitive features:
- Ethanolic solvent systems, especially embodiments using 70% ethanol or ethanol-only solvents, if the competitor’s formulation matches dependent claim frameworks.
- Two-dose schedules within a 6–10 hour spacing after bedtime application.
What formulation and manufacturing/IP barriers are implied by the claim language?
Answer: The claim language implies barriers mainly on formulation identity and performance equivalence rather than on manufacturing steps.
Formulation barriers
- Compound identity and concentration: 1–25%.
- For certain embodiments: 70% ethanol and 5% solution embodiments.
- Solvent system: ethanol-only or isopropyl alcohol/ethanol.
Performance barriers
- Sweat reduction endpoints and duration.
- Comparative equivalency to topical glycopyrrolate.
- Comparative safety.
This creates a landscape where routine reformulation may not reduce infringement risk unless it avoids claim elements like actives, dosing time, or meeting the comparative performance/safety requirements.
Timing and regimen boundaries: when does infringement occur under this claim?
Answer: Infringement risk is tied to administration before bedtime and to the resulting reduction in sweat production sustained for at least 6 hours. Dependent claim risk expands with repeat dosing 6–10 hours later and with daily dosing frequency choices.
Key timing parameters
- Primary application: before bedtime
- Minimum effect duration: ≥6 hours
- Optional second application window: 6–10 hours after initial time
- Dependent efficacy windows:
- ~8–24 hours (Claim 2)
- ~8–12 hours (Claim 3)
- Narrower performance point: ~50% (Claim 5)
How does US 10,383,846 compare with typical hyperhidrosis topical patents (high-level claim pattern)?
Answer: Typical hyperhidrosis topical patents may claim: (a) active ingredients (often anticholinergics such as glycopyrrolate), (b) formulation improvements (vehicles, penetration enhancers), or (c) dosing regimens. US 10,383,846 differentiates itself by combining:
- a narrow named active set (two pyrrolidinium bromides),
- bedtime-specific timing,
- quantitative sweat-reduction performance thresholds, and
- comparative equivalency and safety improvement versus topical glycopyrrolate.
This combination raises the bar for competitors to prove noninfringement on both efficacy and safety.
Key Takeaways
- Claim scope: US 10,383,846 is a performance-and-comparison method/dosing patent for topical hyperhidrosis using two specified pyrrolidinium bromide compounds at ~1% to ~25%, applied before bedtime.
- Core limitations: infringement hinges on meeting ≥25% sweat reduction for ≥6 hours, plus substantially equivalent sweat reduction to topical glycopyrrolate at the same concentration and improved safety versus topical glycopyrrolate.
- Design-around levers: active identity (move off the two named compounds), timing (avoid “before bedtime”), and failure to meet the comparative efficacy/safety requirements.
- Product hooks in dependents: ethanol/solvent embodiments (including 70% ethanol and ethanol-only) and repeat dosing within 6–10 hours elevate infringement risk for matched formulations/regimens.
- Estate/opponent landscape limits: without the patent family bibliographic record, FDA product linkage, and citation/litigation history, a complete “patent landscape” mapping across related US filings, continuation coverage, and Orange Book listing cannot be credibly produced from the claim text alone.
FAQs
-
Does US 10,383,846 cover topical hyperhidrosis treatments that use generic glycopyrrolate itself?
The independent claims require one of the two named pyrrolidinium bromide compounds and include comparative performance versus topical glycopyrrolate; coverage depends on using the claimed compounds plus the method constraints.
-
If a product is applied in the morning instead of “before bedtime,” is it automatically outside the claims?
The claims expressly require “before bedtime” as a dosing condition, creating a potential noninfringement pathway for dosing schedules that do not satisfy that limitation.
-
Are different formulation types (gel vs cream vs foam) outside the patent?
Dependent claims list many formulation types as encompassed. The independent claim only requires a pharmaceutically acceptable vehicle, so formulation type alone is unlikely to be a safe design-around if the active and method endpoints are met.
-
What role do the “substantially equivalent” and “improved safety profile” limitations play in litigation?
They create comparative, evidence-heavy elements tied to sweat-production equivalency versus topical glycopyrrolate and an improved safety showing, both of which can be disputed.
-
Do dependent claims on 70% ethanol and 5% solution create additional infringement risk even for products not matching those solvents?
Those dependent limitations add narrower embodiment coverage. A product that does not use the specified ethanol/solution features may avoid those dependent claims, though it could still face independent claim risk if it satisfies all independent elements.
References (APA)
No sources were provided or cited in the prompt beyond the claim text itself.
